Publications by authors named "B J Doranz"
Article Synopsis
- Specificity profiling is crucial for monoclonal antibodies and biotherapeutics like CAR-T cells before human trials, as traditional methods often miss off-target binding.
- Cell-based protein arrays provide a more reliable way to evaluate mAb specificity by examining interactions with around 6,000 human membrane proteins in live cells.
- Our findings show a concerning 33% off-target binding rate in lead mAb candidates, with 20% of currently marketed therapeutic mAbs affected, indicating off-target binding may significantly contribute to adverse events and drug failures.
Article Synopsis
- - SARS-CoV-2 is continuously evolving, posing challenges to existing vaccines and treatments, which has led to the development of a new pipeline for creating effective VHH antibodies and bispecifics to neutralize various virus variants.
- - High-affinity VHH antibodies were discovered through targeted phage library techniques, resulting in a bispecific construct that effectively combats multiple SARS-CoV-2 variants, showing enhanced resistance to antigenic escape.
- - The new tetravalent bispecific platform enables speedy development and production of antibodies, providing flexible and potent responses to emerging variants, making it a promising method for ongoing viral management.
Influenza B viruses (IBVs) comprise a substantial portion of the circulating seasonal human influenza viruses. Here, we describe the isolation of human monoclonal antibodies (mAbs) that recognized the IBV neuraminidase (NA) glycoprotein from an individual following seasonal vaccination. Competition-binding experiments suggested the antibodies recognized two major antigenic sites.
View Article and Find Full Text PDFMonoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP) are the standard of care for Ebola virus disease (EVD). Anti-GP mAbs targeting the stalk and membrane proximal external region (MPER) potently neutralize EBOV . However, their neutralization mechanism is poorly understood because they target a GP epitope that has evaded structural characterization.
View Article and Find Full Text PDFArticle Synopsis
- The emergence of SARS-CoV-2 variants with reduced vaccine effectiveness shows the need for new vaccine designs that provide wider protection.
- This study evaluates the antibody response from a novel vaccine, the Spike Ferritin Nanoparticle (SpFN), in non-human primates, particularly focusing on the antibodies that target different regions of the virus's Spike protein.
- Six potent neutralizing antibodies were identified, demonstrating broad effectiveness against various sarbecovirus variants, including Delta and Omicron, with one antibody showing strong protection in murine studies.